Clinical trial · Observational
Quality of Life Among Testicular Cancer Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Testicular Cancer is the most prevalent malignancy among men between 20 and 34 years of age, with incidence rates rising in western countries including Israel. Cure rate of testicular cancer exceeds 90% with modern treatments. Thus issues such as quality of life (QoL), coping, effects on couple relationships, cognitive function, cognitive orientation and hormonal function become increasingly important. This study aims to assess all these issues using validated, reproducible questionnaires and hormonal plasma levels, and compare them between testicular cancer survivors and controls.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Spermatic Cord Torsion | — | UNRESOLVED | — |
| Testicular Hydrocele | — | UNRESOLVED | — |
| Testicular Neoplasms | Testicular Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Varicocele | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hormonal Function measurement | Other | — | UNRESOLVED |
| Questionnaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Testicular cancer survivors
- description
- Patients treated for testicular cancer, will receive questionnaires and hormonal function measurement.
- interventionNames
- Other: Questionnaires
- Other: Hormonal Function measurement
- label
- Surgery for benign testicular problems
- description
- Patients treated for benign testicular conditions, will receive questionnaires and hormonal function measurement.
- interventionNames
- Other: Questionnaires
- Other: Hormonal Function measurement
- label
- Healthy males
- description
- Healthy volunteers, will receive questionnaires and hormonal function measurement.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: Group1: Testicular cancer long-term survivors * Male subjects between 2 to 10 years after testicular cancer diagnosis, who have completed treatment and are regarded as complete responders. * Able to give informed consent Group 2: Benign testicular conditions patients * Male subjects between 2 to 10 years after testicular surgery due to a benign condition. * Able to give informed consent Group 3: Healthy Controls * Healthy males * Able to give informed consent Partners of males from above 3 groups * Females or males * In a couple relationship with a man of 1 of the above groups, for 1 year or longer. * Able to give informed consent Exclusion criteria: Group1: Testicular cancer long-term survivors * Inability to answer questionnaires (i.e due to mental impairment). * Another malignancy, other than non-invasive skin basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). * Testicular cancer recurrence. Group 2: Benign testicular conditions patients * Inability to answer questionnaires. * Any history of malignancy other than non-invasive skin BCC or SCC. Group 3: Healthy Controls * Inability to answer questionnaires. * Any history of malignancy other than non-invasive skin BCC or SCC. * Any history of testicular surgery or diagnosed testicular problems in adulthood or childhood. Partners of males from above 3 groups \- Inability to answer questionnaires.
References
Publications (0)
Data not yet available